Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jan 18;8(3):322-326.
doi: 10.1515/dx-2020-0154. Print 2021 Aug 26.

Clinical assessment of the Roche SARS-CoV-2 rapid antigen test

Gian Luca Salvagno  1   2 , Gianluca Gianfilippi  3 , Damiano Bragantini  4 , Brandon M Henry  5 , Giuseppe Lippi  2
Affiliations
Free article
Comparative Study

Clinical assessment of the Roche SARS-CoV-2 rapid antigen test

Gian Luca Salvagno et al. Diagnosis (Berl). .
Free article

Abstract

Objectives: Novel point-of-care antigen assays present a promising opportunity for rapid screening of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The purpose of this study was the clinical assessment of the new Roche SARS-CoV-2 Rapid Antigen Test.

Methods: The clinical performance of Roche SARS-CoV-2 Rapid Antigen Test was evaluated vs. a reverse transcription polymerase chain reaction (RT-PCR) laboratory-based assay (Seegene AllplexTM2019-nCoV) in nasopharyngeal swabs collected from a series of consecutive patients referred for SARS-CoV-2 diagnostics to the Pederzoli Hospital (Peschiera del Garda, Verona, Italy) over a 2-week period.

Results: The final study population consisted of 321 consecutive patients (mean age, 46 years and IQR, 32-56 years; 181 women, 56.4%), with 149/321 (46.4%) positive for SARS-CoV-2 RNA via the Seegene AllplexTM2019-nCoV Assay, and 109/321 (34.0%) positive with Roche SARS-CoV-2 Rapid Antigen Test, respectively. The overall accuracy of Roche SARS-CoV-2 Rapid Antigen Test compared to molecular testing was 86.9%, with 72.5% sensitivity and 99.4% specificity. Progressive decline in performance was observed as cycle threshold (Ct) values of different SARS-CoV-2 gene targets increased. The sensitivity was found to range between 97-100% in clinical samples with Ct values <25, between 50-81% in those with Ct values between 25 and <30, but low as 12-18% in samples with Ct values between 30 and <37.

Conclusions: The clinical performance of Roche SARS-CoV-2 Rapid Antigen Test is excellent in nasopharyngeal swabs with Ct values <25, which makes it a reliable screening test in patients with high viral load. However, mass community screening would require the use of more sensitive techniques.

Keywords: COVID-19; SARS-CoV-2; antigen; diagnosis; immunoassay.

PubMed Disclaimer

References

    1. Lippi, G, Henry, BM, Bovo, C, Sanchis-Gomar, F. Health risks and potential remedies during prolonged lockdowns for coronavirus disease 2019 (COVID-19). Diagnosis (Berl) 2020;7:85–90. https://doi.org/10.1515/dx-2020-0041.
    1. Lippi, G, Plebani, M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med 2020;58:1063–9. https://doi.org/10.1515/cclm-2020-0240.
    1. Iacobucci, G. Covid-19: testing service wasn’t prepared for increased demand, chief admits. BMJ 2020;370:m3676 and Todd B. The U.S. COVID-19 Testing Failure. Am J Nurs 2020;120;19–20.
    1. Alaa, A, Qian, Z, Rashbass, J, Benger, J, van der Schaar, M. Retrospective cohort study of admission timing and mortality following COVID-19 infection in England. BMJ Open 2020;10:e042712. https://doi.org/10.1136/bmjopen-2020-042712.
    1. Kretzschmar, ME, Rozhnova, G, Bootsma, MCJ, van Boven, M, van de Wijgert, JHHM, Bonten, MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health 2020;5:e452–9. https://doi.org/10.1016/s2468-2667(20)30157-2.

Publication types

MeSH terms

Substances

LinkOut - more resources